BioSig Awarded US Patent Claims for its Universal Notch Filter Technology
February 17 2023 - 7:30AM
-
Patent can remove any fixed frequency interfering with
original signal of interest preserving critical intracardiac
data
-
BioSig now has 56 worldwide fundamental
granted/allowed patents in the field of digital
signal processing
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) an advanced digital signal processing technology company
delivering unprecedented accuracy and precision to intracardiac
signal visualization with its proprietary PURE EP™ System, today
announced that the US Patent Office has issued a utility patent
covering its PURE EP™ universal notch filtering
technology.
Patent No. 11,569,853 was issued on
January 31, 2023 and is entitled
“Universal Notch Filter " and is based on U.S.
Application No. 17/591,008 with a priority date of November 8,
2019. The patent describes and claims systems, methods, and
computer program product embodiments of the PURE EP™ System for
removing any fixed frequency interfering signal from an input
signal without introducing artifacts that are not part of the
original signal of interest.
“This latest patent award further demonstrates our commitment to
developing technology that protects elaborate cardiac signals and
furthers the field of electrophysiology,” said Ken Londoner,
Chairman, CEO and Founder of BioSig Technologies, Inc. “PURE EP™
revitalizes the value of the EGM to help EP’s perform
insight-based, highly targeted ablation procedures for even the
most complex arrhythmias.”
BioSig now has 56 worldwide fundamental granted/allowed, 11
pending U.S. patent applications, and seven European/PCT
applications covering its advanced signal processing
technology. The company also has 13 pending patent
applications in Asia including China, Korea, Japan and Taiwan.
About The PURE EP™ System
The PURE EP™ System is a combination of hardware and software
that enables the real-time acquisition of raw signal data—absent of
unnecessary noise or interference—allowing physicians to make
informed clinical decisions based on clear and precise data. With
the heightened visualization of active signals, the PURE EP™ System
is facilitating personalized patient care and innovations in the
field of electrophysiology.
About BioSig Technologies, Inc.
BioSig Technologies is an advanced digital signal
processing technology company bringing never-before-seen insights
to the treatment of cardiovascular arrhythmias. Through
collaboration with physicians, experts, and healthcare leaders
across the field of electrophysiology (EP), BioSig is committed to
addressing healthcare’s biggest priorities — saving time, saving
costs, and saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial
launch and an integral part of well-respected healthcare systems,
such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland
Clinic, and Kansas City Heart Rhythm Institute. In a blinded
clinical study recently published in the Journal of
Cardiovascular Electrophysiology, electrophysiologists rated PURE
EP™ as equivalent or superior to conventional systems for 93.6% of
signal samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.1
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024